LENZ Therapeutics (NASDAQ:LENZ) Lowered to Sell Rating by Wall Street Zen

LENZ Therapeutics (NASDAQ:LENZ) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

LENZ has been the subject of several other reports. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Thursday, January 22nd. Finally, William Blair reaffirmed an “outperform” rating on shares of LENZ Therapeutics in a report on Tuesday, March 10th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $55.50.

LENZ Therapeutics Stock Down 8.8%

Shares of NASDAQ LENZ opened at $10.48 on Friday. The business’s 50 day moving average price is $14.57 and its two-hundred day moving average price is $25.15. The company has a market cap of $327.92 million, a PE ratio of -4.97 and a beta of 0.52. LENZ Therapeutics has a twelve month low of $10.44 and a twelve month high of $50.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP bought a new stake in shares of LENZ Therapeutics in the 3rd quarter valued at about $27,000. Bfsg LLC bought a new position in shares of LENZ Therapeutics during the third quarter worth about $30,000. State of Wyoming acquired a new position in shares of LENZ Therapeutics in the fourth quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of LENZ Therapeutics in the fourth quarter worth approximately $32,000. Finally, Osaic Holdings Inc. boosted its holdings in LENZ Therapeutics by 2,146.2% in the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after acquiring an additional 1,116 shares during the last quarter. 54.32% of the stock is owned by institutional investors and hedge funds.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.